A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054). (Q33399406)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22291006%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

title

A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22291006%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

main subject

phase I clinical trial

0 references

temozolomide

0 references

author

Martin J van den Bent

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22291006%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

4

Denis Lacombe

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22291006%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

2

Marc Sanson

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22291006%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

author name string

Roy Rampling

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22291006%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Thiery Gorlia

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22291006%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Christina Lai

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22291006%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Myriam Gharib

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22291006%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Walter Taal

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22291006%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Clemens Stoffregen

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22291006%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Rodney Decker

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22291006%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

publication date

29 January 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22291006%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22291006%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22291006%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22291006%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

page(s)

344-350

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22291006%20AND%20SRC:MED&resulttype=core&format=json

Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context

21 January 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280806

Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280806

A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280806

Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280806

Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma--analysis of O6-methylguanine-DNA methyltransferase status

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280806

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280806

LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280806

The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280806

The biology of VEGF and its receptors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280806

Vascular-specific growth factors and blood vessel formation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280806

Intracerebral hemorrhage secondary to thrombocytopenia in a patient treated with temozolomide

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280806

Enzastaurin in the treatment of recurrent glioblastoma: a promise that did not materialize

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280806

Safety, tolerability, QTc evaluation, and pharmacokinetics of single and multiple doses of enzastaurin HCl (LY317615), a protein kinase C-beta inhibitor, in healthy subjects.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280806

Synergistic antiglioma activity of radiotherapy and enzastaurin.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280806

The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280806

Response criteria for phase II studies of supratentorial malignant glioma

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280806

Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22291006

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/NEUONC/NOR221

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22291006%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22291006%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22291006%20AND%20SRC:MED&resulttype=core&format=json